Search via Getty Images

Who Should Decide If Gene Therapy Is Too Risky, Patients or the FDA?

BioViva and its controversial CEO Liz Parrish want to bring experimental gene therapies to patients prior to approval by regulators in a quest to cure aging.

BioViva CEO Liz Parrish | BioViva

The death of Jesse Gelsinger from an experimental gene therapy in 1999 still casts a shadow over the field.